Biological response modifiers render tumor cells susceptible to autologous effector mechanisms by influencing adhesion receptors.

Abstract:

:Adhesion molecules such as CD2 and its ligand CD58 (LFA-3), as well as CD11a/18 (LFA-1) and CD54 (ICAM-1) regulate not only cell to cell attachment but also participate in lymphocyte activation, recirculation, and effector function including cytolytic activity towards tumor cells. We have investigated the role of CD2/CD58 and CD11a/18/CD54 interactions in cellular immune responses directed towards freshly recovered human T cell leukemias. Downregulation of CD54 and CD58 were observed to correlate with enhanced numbers of blasts in circulation and lack of susceptibility to killing by autologous cytotoxic lymphocytes. Furthermore, culturing tumor cells with recombinant TNF-alpha conditioned medium resulted in reinduction of CD54 and CD58 expression and susceptibility to lymphocyte mediated resulted in reinduction of CD54 and CD58 expression and susceptibility to lymphocyte mediated lysis in vitro. Our findings support the view that adhesion molecules play a pivotal role for tumor cell biology in vivo and stress the point that successful immunotherapy of malignant disease may be facilitated by influencing not only the immune response itself but also adhesion molecules on the malignant tumor targets.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Schirren CA,Völpel H,Hoffmann JC,Henning SW,Qiao L,Autschbach F,Dengler TJ,Döhner H,Meuer SC

doi

10.3109/10428199309147353

subject

Has Abstract

pub_date

1993-05-01 00:00:00

pages

25-33

issue

1-2

eissn

1042-8194

issn

1029-2403

journal_volume

10

pub_type

杂志文章
  • The role of Aktand RAFTK in beta1 integrin mediated survival of precursor B-acute lymphoblastic leukemia cells.

    abstract::In this study, we report that the related adhesion focal tyrosine kinase RAFTK, is an upstream kinase in beta1 integrin mediated activation of Akt. Stimulation through beta1 integrins by fibronectin reversed apoptosis induced by adriamycin. Inhibitors of phosphatidylinositol 3-kinase (PI3 kinase)/Akt (LY 294002), tyro...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819021000003009

    authors: Sarkar S,Svoboda M,de Beaumont R,Freedman AS

    更新日期:2002-08-01 00:00:00

  • Myeloperoxidase gene expression in normal granulopoiesis and acute leukemias.

    abstract::Myeloperoxidase (MPO) is an abundant heme protein found in granulocytes and monocytes, which plays an important role in host defense against infection. MPO enzyme activity as determined by light microscopic cytochemistry has long been an important marker used in the diagnosis of acute leukemias and other hematopoietic...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199409049717

    authors: Austin GE,Chan WC,Zhao W,Racine M

    更新日期:1994-10-01 00:00:00

  • CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.

    abstract::Few reports on the successful treatment of T-cell large granular lymphocyte (LGL) leukemia with the humanized anti-CD52 monoclonal antibody alemtuzumab are emerging in the literature. The expression of CD52 by LGLs has not been previously investigated. Using semi-quantitative 2- and 3-color flow cytometry, we document...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500052156

    authors: Osuji N,Del Giudice I,Matutes E,Morilla A,Owusu-Ankomah K,Morilla R,Dunlop A,Catovksy D

    更新日期:2005-05-01 00:00:00

  • Vincristine degradation by serum from leukemic patients: role of myeloperoxidase.

    abstract::Myeloperoxidase (MPO) has been shown to catalyze the in vitro degradation of vincristine (VCR). Given that MPO is a lysosomal enzyme that can be released into the circulation by both normal activated and leukemic myeloid cells, we investigated the possibility that sera from patients with acute myeloblastic leukemia (A...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199609052426

    authors: Schlaifer D,Duchayne E,Demur C,Alvinerie P,Muller C,Attal M,Cooper MR,Payen C,Monsarrat B,Myers CE,Pris J,Laurent G

    更新日期:1996-02-01 00:00:00

  • A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry.

    abstract::The V617F mutation of the JAK2 tyrosine kinase is found in a majority of patients with myeloproliferative disorders. Flow cytometry assays for quantitation of phosphorylated and total protein for JAK2, STAT5, and heat shock proteins (HSPs) were developed to facilitate the study of the JAK/STAT pathway. A cell line hom...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701607576

    authors: Bareng J,Jilani I,Gorre M,Kantarjian H,Giles F,Hannah A,Albitar M

    更新日期:2007-11-01 00:00:00

  • Systemic Irradiation Therapy of Myelomatosis-The Therapeutic Implications of Technique.

    abstract::The pattern of disease relapse in nine patients with multiple myeloma who had received double hemi body irradiation therapy is analysed. This analysis highlights the localisation of these relapses to skeletal areas excluded from initial radiation fields. This phenomenon was also documented in a patient who received sy...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199009042484

    authors: Giles FJ,Lord CD,Gaminarai EJ,Grants IR,Kearney JW,Mills MJ,Newland AC,Nikoskelainen J,Pelliniemi T,Richards JD,Rostom AC,Tobias JS,Trask CT,Goldstone AH

    更新日期:1990-01-01 00:00:00

  • Is there a difference in childhood T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma?

    abstract::To distinguish the similarities or differences between T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL), we retrospectively analyzed the clinical, immunophenotypic, cytogenetic, and molecular characteristics in 37 children diagnosed between December 1990 and December 2003. Compara...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701509772

    authors: Uyttebroeck A,Vanhentenrijk V,Hagemeijer A,Boeckx N,Renard M,Wlodarska I,Vandenberghe P,Depaepe P,De Wolf-Peeters C

    更新日期:2007-09-01 00:00:00

  • Low Beclin-1 expression predicts improved overall survival in patients treated with immunomodulatory drugs for multiple myeloma and identifies autophagy inhibition as a promising potentially druggable new therapeutic target: an analysis from The Austrian

    abstract::Beclin-1 is a key regulator of autophagy and has been suggested to be involved in the development of drug resistance in multiple myeloma (MM). We analyzed the expression of Beclin-1 in a retrospective cohort of 70 MMs. Beclin-1 expression did not influence overall survival (OS) and progression-free survival (PFS) in p...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2016.1144880

    authors: Willenbacher W,Thangavadivel S,Greil R,Willenbacher E,Weger R,Manzl C,Jöhrer K,Brunner A

    更新日期:2016-10-01 00:00:00

  • Case 30: hypereosinophilia.

    abstract::A young man presented with systemic symptoms and marked eosinophilia. Subsequently cyclical weight gain and edema contributed to a diagnosis. ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190600724878

    authors: Marks AJ,Abdalla SH,Cross NC,Bain BJ

    更新日期:2006-08-01 00:00:00

  • Cost-effectiveness of a transplantation strategy compared to melphalan and prednisone in younger patients with multiple myeloma.

    abstract::High dose chemotherapy with autologous stem cell transplantation (ASCT) improves outcomes in patients 65 years of age or less with multiple myeloma. Survival and costs in a cohort of 16 patients who received melphalan and prednisone as part of a clinical trial were compared with those of 36 patients referred to our ce...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.3109/10428190309178811

    authors: Kouroukis CT,O'Brien BJ,Benger A,Marcellus D,Foley R,Garner J,Ingram C,Haines P,Henderson-O'Connor N,Meyer R

    更新日期:2003-01-01 00:00:00

  • First-line treatment of follicular lymphoma: a patient-oriented algorithm.

    abstract::Follicular lymphoma is an indolent and usually incurable disease. It has been, therefore, traditionally approached either by watch and wait or with single-agent treatments with the purpose of maintaining a good quality of life for a prolonged time. The emergence of more aggressive regimens including polychemotherapy, ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190802713513

    authors: Feuerlein K,Zucca E,Ghielmini M

    更新日期:2009-03-01 00:00:00

  • Central venous catheter-related complications in patients with hematological malignancies: a retrospective analysis of risk factors and prophylactic measures.

    abstract:UNLABELLED:We retrospectively analyzed the incidence of thrombotic and infectious complications in relation with the use of central venous catheters (CVCs), in a series of patients with hematological malignancies and low platelet and leucocyte counts. PATIENTS AND METHODS:126 patients with hematological malignancies w...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190309178770

    authors: Cortelezzia A,Fracchiolla NS,Maisonneuve P,Moia M,Luchesini C,Ranzi ML,Monni P,Pasquini MC,Lambertenghi-Deliliers G

    更新日期:2003-09-01 00:00:00

  • Relevance of in vitro leukaemia cell survival to short- and long term clinical outcome in AML.

    abstract::In ninety-three cases of newly diagnosed acute myeloid leukaemia (AML) we investigated the importance to short- and long term clinical outcome of the in vitro short term leukaemia cell survival as measured by a 4-day MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide)-assay. In 67 patients treated by i...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199909167393

    authors: Nørgaard JM,Jensen PD,Bendix K,Clausen N,Palshof T

    更新日期:1999-01-01 00:00:00

  • Aggressive chemotherapy for acute leukemia relapsed after transplantation.

    abstract::Bone marrow transplantation procedure has emerged as an effective treatment for hematological malignancies. However, recurrence of leukemia is still the major cause of treatment failure. Subsequent treatment in this category of patients, generally considered incurable, has not been yet standardized. At our institution...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199409051687

    authors: Sica S,Salutari P,Di Mario A,D'Onofrio G,Etuk B,Leone G

    更新日期:1994-09-01 00:00:00

  • Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes.

    abstract::The clinical significance and mechanisms of TET2 are not well defined in myeloid malignancies. We detected TET2 mutations and assayed its catalyzing conversion product 5-hydroxymethylcytosine (5-hmC) in 61 Chinese patients with MDS. Ten patients were identified to have TET2 mutations (16.4%). 5-hmC levels in patients ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.778408

    authors: Liu X,Zhang G,Yi Y,Xiao L,Pei M,Liu S,Luo Y,Zhong H,Xu Y,Zheng W,Shen J

    更新日期:2013-11-01 00:00:00

  • Treatment of young relapsed Hodgkin's disease patients with high-dose chemotherapy followed by peripheral blood stem cell transplantation.

    abstract::Four patients less than 20 years of age with Hodgkin's disease, who had developed either second or third relapse, were treated with high-dose chemotherapy followed by peripheral blood stem cell transplantation (PBSCT). Peripheral blood stem cells (PBSC) were collected after the administration of high-dose cytosine ara...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199509059652

    authors: Matsuzaki A,Okamura J,Nagatoshi Y,Kai T,Ohga S,Gondo H,Inaba S,Ueda K

    更新日期:1995-08-01 00:00:00

  • Novel tumor markers provide improved prediction of survival after diagnosis of human immunodeficiency virus (HIV)-related diffuse large B-cell lymphoma.

    abstract::Existing prognostic tools for HIV + diffuse large B-cell lymphoma (DLBCL) fail to accurately predict patient outcomes. To develop a novel prognostic algorithm incorporating molecular tumor characteristics and HIV disease factors, we included 80 patients with HIV-related DLBCL diagnosed between 1996 and 2007. Immunohis...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2017.1334121

    authors: Chao C,Silverberg MJ,Chen LH,Xu L,Martínez-Maza O,Abrams DI,Zha HD,Haque R,Said J

    更新日期:2018-02-01 00:00:00

  • Bone marrow aplasia with prominent atypical plasmacytic proliferation preceding acute lymphoblastic leukemia.

    abstract::A two-year-old boy presented with pancytopenia. Bone marrow examination revealed an aplastic marrow with prominent immature plasma cell proliferation, which mimicked plasma cell leukemia. Immunohistochemistry, however, revealed a polyclonal population consistent with a reactive process, excluding plasma cell neoplasia...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199909145722

    authors: Kikuchi M,Ohsaka A,Chiba Y,Sato M,Muraosa Y,Hoshino H

    更新日期:1999-09-01 00:00:00

  • Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma.

    abstract::Plasmablastic lymphoma (PBL) is a distinct variant of diffuse large B-cell lymphoma initially described in HIV-positive patients. Several studies have reported the occurrence of PBL in HIV-negative patients, but comparative data are lacking. The goal of this study was to compare the characteristics of HIV-positive and...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.516040

    authors: Castillo JJ,Winer ES,Stachurski D,Perez K,Jabbour M,Milani C,Colvin G,Butera JN

    更新日期:2010-11-01 00:00:00

  • Mutation of the ATM gene is not involved in the pathogenesis of either follicle center lymphoma or its transformation to higher-grade lymphoma.

    abstract::Loss of function of the ataxia-telangiectasia mutated (ATM) gene, located on human chromosome 11q22-23, is the cause of ataxia-telangiectasia (A-T), which is associated with an extremely high risk for lymphoma. Abnormalities in 11q22-23, including deletions and mutations of the ATM gene, have been reported in T-cell p...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190290021623

    authors: Lossos IS,Thorstenson YR,Wayne TL,Oefner PJ,Levy R,Chu G

    更新日期:2002-05-01 00:00:00

  • Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future.

    abstract::Abstract Acute graft-versus-host disease (GVHD) has compromised and continues to compromise the benefits associated with allogeneic hematopoietic cell transplant to cure malignant and non-malignant diseases. Pharmacologic interventions to prevent GVHD have emerged as a major objective of research in the immunology and...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2012.762978

    authors: Ram R,Storb R

    更新日期:2013-08-01 00:00:00

  • DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma.

    abstract::We performed a phase II study of dexamethasone, ifosfamide, idarubicin and etoposide (DIZE) in patients with relapsed or refractory Hodgkin's (HL) and non-Hodgkin's lymphoma (NHL). The regimen consisted of dexamethasone (20 mg i.v. days 1-4), idarubicin (8 mg/m2 i.v. days 1+2), continuous infusion (c.i.) of ifosfamide...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199809059229

    authors: Reiser M,Schnell R,Straub G,Borchmann P,Wilhelm M,Ubelacker R,Wörmann B,Münch R,Diehl V,Engert A

    更新日期:1998-10-01 00:00:00

  • Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all.

    abstract::The application of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has revolutionized the treatment of acute promyelocytic leukemia (APL). More than 80-90% of patients are expected to be cured with a combination of ATRA, ATO and/or chemotherapy. In this review, we focus on the remaining obstacles to a cure f...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2019.1613540

    authors: Stahl M,Tallman MS

    更新日期:2019-12-01 00:00:00

  • Megakaryocytic leukemia and platelet factor 4.

    abstract::The de novo megakaryocytic leukemia fulfilling the FAB criteria is still an uncommonly recognized variant of acute leukemia. Many studies have shown that the megakaryocytic leukemic events may occur at a pluripotent stem cell level and clinical observations reveal that the megakaryocytic leukemias are diverse entities...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199209051011

    authors: Ryo R,Yasunaga M,Saigo K,Yamaguchi N

    更新日期:1992-11-01 00:00:00

  • Advances in umbilical cord blood transplant: a summary of the 11th International Cord Blood Symposium, San Francisco, 6-8 June 2013.

    abstract::The 11th International Cord Blood Symposium was devoted to advances in umbilical cord blood (UCB) research and transplant. Results of cord blood transplant (UCB SCT) for congenital storage disease and hemoglobinopathies are encouraging, but UCB SCT may also be useful for older adults with hematologic malignancies, and...

    journal_title:Leukemia & lymphoma

    pub_type:

    doi:10.3109/10428194.2013.837162

    authors: van Besien K

    更新日期:2014-08-01 00:00:00

  • Biochemical modulation of arabinosylcytosine for therapy of leukemias.

    abstract::Analysis of different ribonucleotide reductase inhibitors to modulate arabinosylcytosine (ara-C) metabolism suggested that pretreatment with arabinosyl-2-fluoroadenine (F-ara-A) significantly potentiated the rate of ara-CTP (5'-triphosphate of ara-C) accumulation in both quiescent lymphocytes (p = 0.046) and in cyclin...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199309149122

    authors: Gandhi V,Estey E,Keating MJ,Plunkett W

    更新日期:1993-01-01 00:00:00

  • Cranial irradiation in adults diagnosed with acute myelogenous leukemia presenting with hyperleukocytosis and neurologic dysfunction.

    abstract::This study describes our institution's experience using whole brain radiation therapy (WBRT) to treat patients with acute myelogenous leukemia (AML) presenting with hyperleukocytosis. After approval by the institutional review board, we identified patients with AML and hyperleukocytosis using hospital records. The pri...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.797088

    authors: Ferro A,Jabbour SK,Taunk NK,Aisner J,Cohler A,Somalya S,Goyal S

    更新日期:2014-01-01 00:00:00

  • Regression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapy.

    abstract::We describe an HIV-infected 44-year-old man who presented 1 month after discontinuation of HAART therapy with a large mass extending from the mediastinum, enclosing the heart and extending through the diaphragm to the epigastric region. Biopsies subsequently revealed a highly aggressive non-Hodgkin's lymphoma (NHL) pr...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190290006260

    authors: Nasta SD,Carrum GM,Shahab I,Hanania NA,Udden MM

    更新日期:2002-02-01 00:00:00

  • Leukoencephalopathy in childhood acute lymphoblastic leukemia with t(1;19).

    abstract::To clarify the incidence of leukoencephalopathy in patients with t(1;19) and their clinical characteristics, we studied 239 acute lymphoblastic leukemia (ALL) cases. The 1;19 translocation was found in 20 (8.5%) of the 239 children with ALL. Leukoencephalopathy occurred in 2 (10%) patients with t(1;19) during the earl...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199909093734

    authors: Shikano T,Kobayashi R,Ishikawa Y

    更新日期:1999-03-01 00:00:00

  • Mediastinal large-cell lymphoma with sclerosis refractory to conventional chemotherapy can respond after daily oral cyclophosphamide.

    abstract::Mediastinal large-cell lymphoma with sclerosis (MLCLS) is a distinctive subtype of non-Hodgkin's lymphoma (NHL) with unique clinicopathology aspects and aggressive behavior. Prompt diagnosis and aggressive chemotherapy followed by consolidation radiotherapy may result in long-term survival in the majority of cases. Ho...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199809058396

    authors: Benboubker L,Linassier C,Delain M,Demuret A,Calais G,Dequin PF,Lamagnere JP,Colombat P

    更新日期:1998-03-01 00:00:00